Mori K - Search Results

1

Identification of a novel oncogenic mutation of FGFR4 in gastric cancer.

Futami T, Kawase T, Mori K, Asaumi M, Kihara R, Shindoh N, Kuromitsu S. Futami T, et al. Among authors: mori k. Sci Rep. 2019 Oct 10;9(1):14627. doi: 10.1038/s41598-019-51217-6. Sci Rep. 2019. PMID: 31601997 Free PMC article.

2

The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.

Mori M, Ueno Y, Konagai S, Fushiki H, Shimada I, Kondoh Y, Saito R, Mori K, Shindou N, Soga T, Sakagami H, Furutani T, Doihara H, Kudoh M, Kuromitsu S. Mori M, et al. Among authors: mori k. Mol Cancer Ther. 2014 Feb;13(2):329-40. doi: 10.1158/1535-7163.MCT-13-0395. Epub 2014 Jan 13. Mol Cancer Ther. 2014. PMID: 24419060

3

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.

Mori M, Kaneko N, Ueno Y, Yamada M, Tanaka R, Saito R, Shimada I, Mori K, Kuromitsu S. Mori M, et al. Among authors: mori k. Invest New Drugs. 2017 Oct;35(5):556-565. doi: 10.1007/s10637-017-0470-z. Epub 2017 May 17. Invest New Drugs. 2017. PMID: 28516360 Free PMC article.

4

Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models.

Nakayama A, Nagashima T, Nishizono Y, Kuramoto K, Mori K, Homboh K, Yuri M, Shimazaki M. Nakayama A, et al. Among authors: mori k. Br J Cancer. 2022 Mar;126(5):744-753. doi: 10.1038/s41416-021-01629-x. Epub 2021 Nov 18. Br J Cancer. 2022. PMID: 34795410 Free PMC article.

5

Discovery of N-{2-Methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N'-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine (ASP3026), a Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor.

Iikubo K, Kondoh Y, Shimada I, Matsuya T, Mori K, Ueno Y, Okada M. Iikubo K, et al. Among authors: mori k. Chem Pharm Bull (Tokyo). 2018;66(3):251-262. doi: 10.1248/cpb.c17-00784. Chem Pharm Bull (Tokyo). 2018. PMID: 29491259 Free article.

6

Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity.

Imaizumi T, Akaiwa M, Abe T, Nigawara T, Koike T, Satake Y, Watanabe K, Kaneko O, Amano Y, Mori K, Yamanaka Y, Nagashima T, Shimazaki M, Kuramoto K. Imaizumi T, et al. Among authors: mori k. Bioorg Med Chem. 2022 Oct 1;71:116949. doi: 10.1016/j.bmc.2022.116949. Epub 2022 Jul 30. Bioorg Med Chem. 2022. PMID: 35926326

7

Novel strategy to boost oral anticoagulant activity of blood coagulation enzyme inhibitors based on biotransformation into hydrophilic conjugates.

Ishihara T, Koga Y, Mori K, Sugasawa K, Iwatsuki Y, Hirayama F. Ishihara T, et al. Among authors: mori k. Bioorg Med Chem. 2014 Nov 15;22(22):6324-32. doi: 10.1016/j.bmc.2014.09.059. Epub 2014 Oct 19. Bioorg Med Chem. 2014. PMID: 25438755

8

Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors.

Imaizumi T, Shimada I, Satake Y, Yamaki S, Koike T, Nigawara T, Kaneko O, Amano Y, Mori K, Yamanaka Y, Nakayama A, Nishizono Y, Shimazaki M, Nagashima T, Kuramoto K. Imaizumi T, et al. Among authors: mori k. Bioorg Med Chem. 2024 Jan 15;98:117581. doi: 10.1016/j.bmc.2023.117581. Epub 2023 Dec 27. Bioorg Med Chem. 2024. PMID: 38176113

9

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.

Tarver TC, Hill JE, Rahmat L, Perl AE, Bahceci E, Mori K, Smith CC. Tarver TC, et al. Among authors: mori k. Blood Adv. 2020 Feb 11;4(3):514-524. doi: 10.1182/bloodadvances.2019000919. Blood Adv. 2020. PMID: 32040554 Free PMC article.

10

Small-world phenomena in chemical library networks: application to fragment-based drug discovery.

Tanaka N, Ohno K, Niimi T, Moritomo A, Mori K, Orita M. Tanaka N, et al. Among authors: mori k. J Chem Inf Model. 2009 Dec;49(12):2677-86. doi: 10.1021/ci900123v. J Chem Inf Model. 2009. PMID: 19961207

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,618 results

Search Page

Filters